The American Journal of Medecine advises hydroxychloroquine for COVID

burtlancast

Member
Joined
Jan 1, 2013
Messages
3,263
August 2020 article.

Pathophysiological Basis and Rationale for EarlyOutpatient Treatment of SARS-CoV-2 (COVID-19)Infection

"Hydroxychloroquine (HCQ) is an antimalarial/anti-inflammatory
drug that impairs endosomal transfer of virions
within human cells. HCQ is also a zinc ionophore that
conveys zinc intracellularly to block the SARS-CoV-2
RNA-dependent RNA polymerase, which is the core
enzyme of the virus replication.21 The currently completed
retrospective studies and randomized trials have generally
shown these findings: 1) when started late in the hospital
course and for short durations of time, antimalarials appear
to be ineffective, 2) when started earlier in the hospital
course, for progressively longer durations and in outpatients,
antimalarials may reduce the progression of disease,
prevent hospitalization, and are associated with reduced
mortality
.22−25 In a retrospective inpatient study of 2541
patients hospitalized with COVID-19, therapy associated
with an adjusted reduction in mortality was HCQ alone
(hazard ratio

= 0.34, 95% confidence interval [CI]
0.25-0.46, P <0.001) and HCQ with azithromycin
(HR = 0.29, 95% CI 0.22-0.40, P <0.001).23 HCQ was
approved by the US Food and Drug Administration in
1955, has been used by hundreds of millions of people
worldwide since then, is sold over the counter in many
countries, and has a well-characterized safety profile that
should not raise undue alarm
.25,26 Although asymptomatic
QT prolongation is a well-recognized and infrequent (<1%)
complication of HCQ, it is possible that in the setting of
acute illness symptomatic arrhythmias could develop. Data
safety and monitoring boards have not declared safety concerns
in any clinical trial published to date. Rare patients
with a personal or family history of prolonged QT syndrome
and those on additional QT prolonging, contraindicated
drugs (eg, dofetilide, sotalol) should be treated with
caution and a plan to monitor the QTc in the ambulatory
setting. A typical HCQ regimen is 200 mg bid for 5 days
and extended to 30 days for continued symptoms. A minimal
sufficient dose of HCQ should be used, because in
excessive doses the drug can interfere with early immune
response to the virus."
 

haidut

Member
Forum Supporter
Joined
Mar 18, 2013
Messages
19,798
Location
USA / Europe
August 2020 article.

Pathophysiological Basis and Rationale for EarlyOutpatient Treatment of SARS-CoV-2 (COVID-19)Infection

"Hydroxychloroquine (HCQ) is an antimalarial/anti-inflammatory
drug that impairs endosomal transfer of virions
within human cells. HCQ is also a zinc ionophore that
conveys zinc intracellularly to block the SARS-CoV-2
RNA-dependent RNA polymerase, which is the core
enzyme of the virus replication.21 The currently completed
retrospective studies and randomized trials have generally
shown these findings: 1) when started late in the hospital
course and for short durations of time, antimalarials appear
to be ineffective, 2) when started earlier in the hospital
course, for progressively longer durations and in outpatients,
antimalarials may reduce the progression of disease,
prevent hospitalization, and are associated with reduced
mortality
.22−25 In a retrospective inpatient study of 2541
patients hospitalized with COVID-19, therapy associated
with an adjusted reduction in mortality was HCQ alone
(hazard ratio

= 0.34, 95% confidence interval [CI]
0.25-0.46, P <0.001) and HCQ with azithromycin
(HR = 0.29, 95% CI 0.22-0.40, P <0.001).23 HCQ was
approved by the US Food and Drug Administration in
1955, has been used by hundreds of millions of people
worldwide since then, is sold over the counter in many
countries, and has a well-characterized safety profile that
should not raise undue alarm
.25,26 Although asymptomatic
QT prolongation is a well-recognized and infrequent (<1%)
complication of HCQ, it is possible that in the setting of
acute illness symptomatic arrhythmias could develop. Data
safety and monitoring boards have not declared safety concerns
in any clinical trial published to date. Rare patients
with a personal or family history of prolonged QT syndrome
and those on additional QT prolonging, contraindicated
drugs (eg, dofetilide, sotalol) should be treated with
caution and a plan to monitor the QTc in the ambulatory
setting. A typical HCQ regimen is 200 mg bid for 5 days
and extended to 30 days for continued symptoms. A minimal
sufficient dose of HCQ should be used, because in
excessive doses the drug can interfere with early immune
response to the virus."

Now, try sharing that on Twitter, Facebook, etc and see what happens :):
 
OP
burtlancast

burtlancast

Member
Joined
Jan 1, 2013
Messages
3,263
Well, what could go wrong ?...:oops
 
P

Peatness

Guest
Has anyone use hydroxychloroquine long term? What are the side effects?
 

Similar threads

Back
Top Bottom